Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma
The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA.
One hundred and thirty-four adult patient data with house dust mite (HDM)-induced AA who had been treated for 2 years were collected. These patient data that we collected were divided into the SLIT group (n = 85) and control group (n = 49). All patients were treated with low to moderate dose of inhaled glucocorticoid and long-acting β2 agonists. Patients in the SLIT group were further treated with D. farinae drops. Clinical scores including the total asthma symptom score (TASS), total asthma medicine score (TAMS), asthma control test (ACT), and peak flow percentage (PEF%) were assessed before treatment and at yearly visits. The presence of adverse events (AEs) were recorded once a month.
Before treatment, the PEF% in the SLIT group was significantly lower than that in the control group (p < 0.05). After 2 years, both treatments were effective in the clinical scores when compared with baseline values (all p < 0.001). Meanwhile, the SLIT group showed significantly lower TASS and TAMS (all p < 0.001) and higher ACT (p < 0.001) and PEF% (p < 0.05) when compared with the control group. No severe systemic AEs were reported.
SLIT with D. farinae drops plus pharmacotherapy is more effective than routine drug treatment in adult patients with AA.
KeywordsAdult patient Allergic asthma Sublingual immunotherapy
We thank the patients for their availability in taking part in this trial.
All financial supports for this clinical trial were provided by the Department of Science and Technology project of Wuzhou City, Guangxi Province, China (Contract No. 201202081).
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.The global asthma report 2014. Available at: http://www.globalasthmareport.org/burde-n/burden.php
- 10.Lind P, Hansen OC, Horn N (1988) The binding of mouse hybridoma and human IgE antibodies to the major fecal allergen, der p I, of Dermatophagoides pteronyssinus. Relative binding site location and species specificity studied by solid-phase inhibition assays with radiolabeled antigen. J Immunol 140(12):4256–4262PubMedGoogle Scholar
- 12.Yasueda H, Mita H, Yui Y et al (1989) Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae. Int Arch Allergy Appl Immunol 88(4):402–407CrossRefPubMedGoogle Scholar
- 13.Bousquet J, Lockey R, Malling HJ (1998) World Health Organization position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl. 44):1–42Google Scholar
- 20.Global Initiative for Asthma (GINA) Executive Committee (2006) Global strategy for asthma management and prevention 1–110Google Scholar
- 23.Schlosser RJ, Smith TL, Mace J et al (2016) Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. https://doi.org/10.1111/all.13048
- 28.García-Robaina JC, Sánchez I, de la Torre F et al (2006) Successful management of mite-allergicasthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 118:1026–1032. https://doi.org/10.1016/j.jaci.2006.07.043 CrossRefPubMedGoogle Scholar
- 30.Mosbech H, Deckelmann R, De Blay F et al (2014) Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134:568–575. https://doi.org/10.1016/j.jaci.2014.03.019 CrossRefPubMedGoogle Scholar
- 33.Li P, Li Q, Huang Z et al (2014) Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases[C]. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.21397